Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Sanofi bets on new CEO to drive sluggish drug sales

In veteran drug salesman Paul Hudson, Sanofi’s 100,000-plus employees are getting a new chief executive who relishes a good commercial fight.

Read More »

Sanofi loses German patent case against Amgen over cholesterol drug

Germany’s highest civil court rejected French drugmaker Sanofi’s bid to fend off a legal challenge by U.S. rival Amgen against Sanofi’s cholesterol drug Praluent.

Read More »

Cholesterol-lowering drugs tied to reduced glaucoma risk

High cholesterol is associated with an increased risk of developing glaucoma, but a new study suggests taking statins to lower cholesterol helps to reduce this risk.

Read More »

Waylivra Approved In EU For Treating FCS

Akcea Therapeutics Inc. and Ionis Pharmaceuticals Inc. announced that Waylivra received conditional marketing authorization from the European Commission as the only therapy for FCS.

Read More »

FDA approves expanded label for Praluent

The U.S. Food and Drug Administration approved Regeneron Pharmaceuticals’ cholesterol drug Praluent as a treatment to cut the risk of heart attacks, stroke and other major cardiovascular events.

Read More »

Gelesis Granted FDA Clearance to Market PLENITY™ — a New Prescription Aid in Weight Management

Gelesis announced that the United States Food and Drug Administration cleared the biotechnology company’s lead product candidate Plenity (Gelesis100) as an aid in weight management in adults with a Body Mass Index (BMI) of 25–40 kg/m2, when used in conjunction with diet and exercise.

Read More »

Sanofi, Regeneron lose U.S. patent challenge to Amgen cholesterol drug

Amgen Inc. said a U.S. jury confirmed the validity of patents on the biotech company’s cholesterol drug Repatha, rejecting a challenge by Regeneron Pharmaceuticals Inc. and Sanofi SA.

Read More »

Push-up capacity may predict men’s heart disease risk

The number of push-ups a man can do in the doctor’s office may be a good predictor of his risk of developing heart disease in the coming years, new research suggests.

Read More »

Sanofi and Regeneron cutting list price of cholesterol drug by 60 percent

Sanofi SA and Regeneron Pharmaceuticals Inc. will slash the U.S. list price of the companies’ potent but expensive cholesterol fighter Praluent by 60 percent.

Read More »

Statins may help prevent diabetes-related eye problems

Diabetic patients who take statins to treat high cholesterol may get an added benefit: a lower risk of damage to the retina, a new study suggests.

Read More »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

June 2019 Focus: Payer access, biotech/biopharma, DTC, rare diseases, and more!

Subscribe

Ad Right Bottom